会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Actinobacillus pleuropneumoniae subunit vaccine
    • 放线杆菌胸膜肺炎放线芽孢杆菌亚单位疫苗
    • US06783764B1
    • 2004-08-31
    • US09387693
    • 1999-08-31
    • Ruud Philip Antoon Maria SegersJoachim Frey
    • Ruud Philip Antoon Maria SegersJoachim Frey
    • A61K4900
    • C12R1/01A61K39/00C07K14/195C07K14/285C12N15/74
    • The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagnostic test for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strains and vaccine strains.
    • 本发明涉及在apxIV基因中具有突变的胸膜肺炎放线杆菌属的减毒细菌,使得不能产生功能性的ApxIV毒素。 本发明还涉及生产这种细菌的方法。 还包括这种细菌的疫苗和用于生产这种疫苗的方法是本发明的一部分。 本发明还涉及包含ApxIV毒素的亚单位疫苗,用于生产这种疫苗的方法以及用于保护动物免受感染胸膜肺炎放线杆菌属细菌的方法。 此外,本发明涉及apxIV基因的启动子。 最后,本发明涉及胸膜肺炎放线杆菌感染的选择性诊断的诊断试验和区分放线杆菌胸膜肺炎放线芽孢杆菌野毒株和疫苗株的诊断试验。